FL-NEORIS
16.5.2018 17:13:07 CEST | Business Wire | Press release
NEORIS today announced it is one of the main sponsors of the DES2018 | Digital Business World Congress, the world’s largest international forum on digital transformation, which will celebrate its third edition in Madrid (IFEMA) May 22-24, 2018.
With the theme “Facing the Digital Avalanche,” the main goal of the #DES2018 (Digital Enterprise Show), is to offer solutions for different business areas, improving competitiveness and promoting digital transformation while ensuring speed and safety. Artificial Intelligence will be in the spotlight as the main trend during the show, as #DES2018 reunites top tech solutions that are driving the development of new business models such as IoT, Cloud, Cybersecurity, Big Data, Blockchain and Digital Marketing, among many others.
As part of its participation in #DES2018, NEORIS will share its views on the dawn of Artificial Intelligence and its implications on the present and future of business and humanity. In a special session titled “Real Intelligence: The True Challenges and Implications of AI”, Anthony DeLima, NEORIS’ CTO and Global Head of Digital Transformation, will explore the rapid evolution of Artificial Intelligence, how it’s transforming our lives and forcing us to question our own future.
“Artificial Intelligence holds the promise of new possibilities for businesses and the human species in general,” said DeLima. “Its capabilities are enabling organizations to dramatically reinvent themselves and ignite new and exciting interactions with customers and their industry. At the same time, the rapid advancements in AI –which are evolving much faster than we think– pose some critical ethical challenges.”
NEORIS knows firsthand how disruptive technologies are critical enablers to produce a digital transformation culture, based on its deep industry knowledge and experience helping customers achieve smarter interactions in the Healthcare, Financial Services, Manufacturing and Telecommunications industries around the globe.
NEORIS will present solutions for these industries, including demos that highlight different AI dimensions to accelerate business transformation in the evolving digital economy.
About NEORIS
NEORIS is a leading global consultancy that co-creates disruptive solutions for digitally aspiring companies to boost their connections with their customers, employees and stakeholders ; ignited by creative teams with deep industry knowledge and technical expertise.
Headquartered in Miami, FL., NEORIS has a network of global delivery centers, design studios and operations in the U.S., Europe, Latin America, Africa, the Middle East and Asia.
More information is available at http://www.neoris.com , on Facebook or Twitter @NEORIS .
View source version on businesswire.com: https://www.businesswire.com/news/home/20180516005948/en/
Contact:
NEORIS
US:
Paula Amador, 305-728-6044
paula.amador@neoris.com
or
Aileen
Abella, 305-310-6377
aileen@aileenabella.com
or
SPAIN:
Ax
Comunicación
Irene Herranz, Tel: + 34 915 612 962
iherranz@axcomunicacion.com
or
Manuel
Álvarez, Tel: + 34 607 558 751
malvarez@axcomunicacion.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease1.5.2026 23:28:00 CEST | Press release
Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi®(ruxolitinib)Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily JakafiJakafi XR will be available for pharmacy orders by May 8 Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501334677/en/ “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meetin
Barilla Hosts Surprise Formula 1® Family Reunion Dinner During Miami Race Weekend1.5.2026 18:08:00 CEST | Press release
Drivers and team members of Formula 1® were reunited with their loved ones during a night that also celebrated the new partnership between Barilla and the Visa Cash App Racing Bulls Formula 1® Team. A special invitation, a table, and a plate of pasta shared by people who are often apart. That’s all it took for Barilla to bring the spirit of togetherness to Miami during the opening day of the FORMULA 1® CRYPTO.COM MIAMI GRAND PRIX 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430832316/en/ Barilla hosts Arvid Lindblad, Mikaela Shiffrin, and Nico Rosberg with Chef Massimo Bottura at Torno Subito, where the Formula 1® community came together for a surprise dinner. Barilla, the Official Pasta Partner of Formula 1®, welcomed team members and their families to Torno Subito Miami, the restaurant by three-Michelin-starred Chef Massimo Bottura, with the kitchen led by Chef Bernardo Paladini, for an evening where engines wer
TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 12:07:00 CEST | Press release
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the
Andersen Consulting styrker sine kompetencer inden for digital transformation med Weexa1.5.2026 10:07:00 CEST | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Weexa, en global leverandør af løsninger inden for digital transformation, B2B-integration og digitalisering af forsyningskæden. Med hovedsæde i Frankrig leverer Weexa end-to-end-tjenester, der hjælper organisationer med at optimere, sikre og skalere deres digitale økosystemer. Virksomheden specialiserer sig i styring af B2B-datastrømme og digitalisering, hvilket muliggør problemfri kommunikation mellem applikationer både internt og på tværs af organisationer gennem teknologier som EDI, API'er og e-fakturering. Weexa tilbyder også SAP-integration og supply chain-løsninger til styring af lager og transport, sideløbende med strategisk rådgivning, projektlevering og vedligeholdelse af tredjepartsapplikationer. Weexa betjener organisationer inden for fødevaresektoren, detailhandel, engros, logistik, transport, bilindustrien, sundheds- og mediesektoren og hjælper globale virksomheder med at optimere deres ydeevne samt at overholde de nyeste
Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 01:17:00 CEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom